Hypertension - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：238頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hypertension - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2014’, provides an overview of the Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2014’, provides an overview of the Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hypertension Overview 10
Therapeutics Development 11
Pipeline Products for Hypertension - Overview 11
Pipeline Products for Hypertension - Comparative Analysis 12
Hypertension - Therapeutics under Development by Companies 13
Hypertension - Therapeutics under Investigation by Universities/Institutes 18
Hypertension - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Hypertension - Products under Development by Companies 24
Hypertension - Products under Investigation by Universities/Institutes 29
Hypertension - Companies Involved in Therapeutics Development 30
Sanofi 30
Eli Lilly and Company 31
GlaxoSmithKline plc 32
Daiichi Sankyo Company, Limited 33
Merck & Co., Inc. 34
Takeda Pharmaceutical Company Limited 35
BioLineRx, Ltd. 36
Novartis AG 37
Biocon Limited 38
Chong Kun Dang Pharmaceutical Corp. 39
Daewoong Pharmaceutical Co., Ltd. 40
Mitsubishi Tanabe Pharma Corporation 41
Bayer AG 42
Toray Industries, Inc. 43
IntelGenx Corp. 44
Medivir AB 45
Compugen Ltd. 46
Palatin Technologies, Inc. 47
Cytokinetics, Incorporated 48
Yuhan Corporation 49
Torrent Pharmaceuticals Limited 50
HanAll Biopharma Co., Ltd. 51
Ahn-Gook Pharmaceutical Co., Ltd. 52
LG Life Sciences, Ltd. 53
DiaMedica Inc. 54
AFFiRiS AG 55
CJ CheilJedang Corp. 56
Ache Laboratorios Farmaceuticos S/A 57
Cyano Biotech GmbH 58
Anacor Pharmaceuticals, Inc. 59
AngioDesign 60
Innopharmax Inc. 61
QUANTUM GENOMICS Corp. 62
vasopharm GmbH 63
Cellceutix Corporation 64
Diakron Pharmaceuticals, Inc. 65
Biolink Group AS 66
miRagen Therapeutics, Inc. 67
MicroDose Therapeutx, Inc. 68
Vicore Pharma AB 69
Kotobuki Pharmaceutical Co., Ltd. 70
RedHill Biopharma Ltd. 71
Kadmon Pharmaceuticals, LLC 72
Ajinomoto Pharmaceuticals Co., Ltd. 73
Hanmi Pharmaceuticals, Co. Ltd. 74
NanoForm Therapeutics Ltd. 75
Arromax Pharmatech, Co. Ltd. 76
AbbVie Inc. 77
China Grand Wuhan General Pharmaceutical Research Institute 78
Hypertension - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 85
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 94
azilsartan medoxomil - Drug Profile 94
(azilsartan medoxomil + chlorthalidone) - Drug Profile 96
(cilnidipine + valsartan) - Drug Profile 97
(azilsartan + amlodipine besylate) - Drug Profile 98
(AHU-377 + valsartan) - Drug Profile 99
(atorvastatin calcium + losartan potassium) - Drug Profile 101
carvedilol CR - Drug Profile 102
(rosuvastatin + telmisartan) - Drug Profile 104
(irbesartan + atorvastatin calcium) - Drug Profile 105
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 106
ZV Combi - Drug Profile 107
pratosartan - Drug Profile 108
carvedilol CR - Drug Profile 109
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 110
(rosuvastatin + valsartan) - Drug Profile 111
CKD-825 - Drug Profile 112
(losartan potassium + hydrochlorothiazide + amlodipine besylate) - Drug Profile 113
XY-1014-KD-2 - Drug Profile 114
PL-3994 - Drug Profile 115
(atorvastatin calcium + losartan potassium) - Drug Profile 117
KD-027 - Drug Profile 118
CS-3150 - Drug Profile 120
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 121
LFF-269 - Drug Profile 122
Potassium Magnesium Citrate - Drug Profile 123
pratosartan - Drug Profile 124
dextromethorphan - Drug Profile 125
QGC-001 - Drug Profile 126
HPT-C/D-3G - Drug Profile 127
(amlodipine besylate + losartan potassium) - Drug Profile 128
(simvastatin + losartan potassium) - Drug Profile 129
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 130
(candesartan + amlodipine besylate) - Drug Profile 131
TAK-272 - Drug Profile 132
MK-7145 IR - Drug Profile 133
MP-157 - Drug Profile 134
AGSAV-301 - Drug Profile 135
MK-8150 - Drug Profile 136
(amlodipine + losartan) - Drug Profile 137
AGSAA-010 - Drug Profile 138
CARD-024 - Drug Profile 139
(rosuvastatin + amlodipine) - Drug Profile 141
(chlorthalidone + telmisartan) - Drug Profile 142
(amlodipine + enalapril maleate) - Drug Profile 143
RB-150 - Drug Profile 145
CJ-30058 - Drug Profile 147
Drug for Hypertension - Drug Profile 148
CGEN-856 - Drug Profile 149
CGEN-857 - Drug Profile 151
DP-3005 - Drug Profile 152
MetPril - Drug Profile 153
KM-732 - Drug Profile 154
Small Molecule to Inhibit Renin for Hypertension - Drug Profile 155
CK-2018571 - Drug Profile 156
doxazosin mesylate - Drug Profile 157
felodipine - Drug Profile 158
Vaccine For Hypertension - Drug Profile 159
epoetin alfa - Drug Profile 160
DM-204 - Drug Profile 161
olmesartan - Drug Profile 162
MGN-2677 - Drug Profile 163
C-21 - Drug Profile 164
GYY-4137 - Drug Profile 166
CK-2018488 - Drug Profile 167
BR-4628 - Drug Profile 168
GTP-0125 - Drug Profile 169
AGNBS-002 - Drug Profile 170
tannic acid - Drug Profile 171
Dual Action Receptor Antagonists - Drug Profile 172
AVE-3085 - Drug Profile 173
carvedilol CR - Drug Profile 174
Bone Morphogenic Protein Inhibitors - Drug Profile 175
Alanine Glyoxylate Aminotransferase-2 - Drug Profile 176
Drug Targeting AMPD2 - Drug Profile 177
AN-3485 - Drug Profile 178
AMX-1008 - Drug Profile 179
VAS-3947 - Drug Profile 180
Drug To Inhibit 11Beta-HSD1 For Hypertension - Drug Profile 181
Helix B Surface Peptide - Drug Profile 182
SOL-1 - Drug Profile 183
Small Molecule to Inhibit Epoxide Hydrolase for Hypertension - Drug Profile 184
TRC-120038 - Drug Profile 185
Peptide Compounds - Drug Profile 186
3,5-Disubstituted Piperidines - Drug Profile 187
Elsartan - Drug Profile 188
S-43126 - Drug Profile 189
TM-5441 - Drug Profile 190
siRNA to Inhibit Angiotensinogen for Hypertension - Drug Profile 191
Endothelin A Receptor Antagonists for Hypertension - Drug Profile 192
Small Molecule to Inhibit Mineralocorticoid Receptor for Hypertension - Drug Profile 193
AGNES-101 - Drug Profile 194
Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases - Drug Profile 195
Tar-1 - Drug Profile 196
AZ-03 - Drug Profile 197
Microginins ACE Inhibitors- Program - Drug Profile 198
ROMK Channel Inhibitors - Drug Profile 199
R-100 - Drug Profile 200
(amlodipine camsylate + losartan potassium) - Drug Profile 202
metoprolol succinate - Drug Profile 203
Hypertension - Recent Pipeline Updates 204
Hypertension - Dormant Projects 214
Hypertension - Discontinued Products 223
Hypertension - Product Development Milestones 224
Featured News & Press Releases 224
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 231
Disclaimer 231
List of Tables
Number of Products under Development for Hypertension, H1 2014 18
Number of Products under Development for Hypertension - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Development, H1 2014 29
Comparative Analysis by Unknown Stage Development, H1 2014 30
Products under Development by Companies, H1 2014 31
Products under Development by Companies, H1 2014 (Contd..1) 32
Products under Development by Companies, H1 2014 (Contd..2) 33
Products under Development by Companies, H1 2014 (Contd..3) 34
Products under Development by Companies, H1 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Hypertension - Pipeline by Sanofi, H1 2014 37
Hypertension - Pipeline by Eli Lilly and Company, H1 2014 38
Hypertension - Pipeline by GlaxoSmithKline plc, H1 2014 39
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 40
Hypertension - Pipeline by Merck & Co., Inc., H1 2014 41
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 42
Hypertension - Pipeline by BioLineRx, Ltd., H1 2014 43
Hypertension - Pipeline by Novartis AG, H1 2014 44
Hypertension - Pipeline by Biocon Limited, H1 2014 45
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 46
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 47
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 48
Hypertension - Pipeline by Bayer AG, H1 2014 49
Hypertension - Pipeline by Toray Industries, Inc., H1 2014 50
Hypertension - Pipeline by IntelGenx Corp., H1 2014 51
Hypertension - Pipeline by Medivir AB, H1 2014 52
Hypertension - Pipeline by Compugen Ltd., H1 2014 53
Hypertension - Pipeline by Palatin Technologies, Inc., H1 2014 54
Hypertension - Pipeline by Cytokinetics, Incorporated, H1 2014 55
Hypertension - Pipeline by Yuhan Corporation, H1 2014 56
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 57
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 58
Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 59
Hypertension - Pipeline by LG Life Sciences, Ltd., H1 2014 60
Hypertension - Pipeline by DiaMedica Inc., H1 2014 61
Hypertension - Pipeline by AFFiRiS AG, H1 2014 62
Hypertension - Pipeline by CJ CheilJedang Corp., H1 2014 63
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 64
Hypertension - Pipeline by Cyano Biotech GmbH, H1 2014 65
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 66
Hypertension - Pipeline by AngioDesign, H1 2014 67
Hypertension - Pipeline by Innopharmax Inc., H1 2014 68
Hypertension - Pipeline by QUANTUM GENOMICS Corp., H1 2014 69
Hypertension - Pipeline by vasopharm GmbH, H1 2014 70
Hypertension - Pipeline by Cellceutix Corporation, H1 2014 71
Hypertension - Pipeline by Diakron Pharmaceuticals, Inc., H1 2014 72
Hypertension - Pipeline by Biolink Group AS, H1 2014 73
Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2014 74
Hypertension - Pipeline by MicroDose Therapeutx, Inc., H1 2014 75
Hypertension - Pipeline by Vicore Pharma AB, H1 2014 76
Hypertension - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2014 77
Hypertension - Pipeline by RedHill Biopharma Ltd., H1 2014 78
Hypertension - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 79
Hypertension - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 80
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 81
Hypertension - Pipeline by NanoForm Therapeutics Ltd., H1 2014 82
Hypertension - Pipeline by Arromax Pharmatech, Co. Ltd., H1 2014 83
Hypertension - Pipeline by AbbVie Inc., H1 2014 84
Hypertension - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute., H1 2014 85
Assessment by Monotherapy Products, H1 2014 86
Assessment by Combination Products, H1 2014 87
Number of Products by Stage and Target, H1 2014 90
Number of Products by Stage and Mechanism of Action, H1 2014 94
Number of Products by Stage and Route of Administration, H1 2014 97
Number of Products by Stage and Molecule Type, H1 2014 100
Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 211
Hypertension - Dormant Projects, H1 2014 221
Hypertension - Dormant Projects (Contd..1), H1 2014 222
Hypertension - Dormant Projects (Contd..2), H1 2014 223
Hypertension - Dormant Projects (Contd..3), H1 2014 224
Hypertension - Dormant Projects (Contd..4), H1 2014 225
Hypertension - Dormant Projects (Contd..5), H1 2014 226
Hypertension - Dormant Projects (Contd..6), H1 2014 227
Hypertension - Dormant Projects (Contd..7), H1 2014 228
Hypertension - Dormant Projects (Contd..8), H1 2014 229
Hypertension - Discontinued Products, H1 2014 230
List of Figures
Number of Products under Development for Hypertension, H1 2014 18
Number of Products under Development for Hypertension - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Products, H1 2014 29
Assessment by Monotherapy Products, H1 2014 86
Assessment by Combination Products, H1 2014 87
Number of Products by Top 10 Target, H1 2014 88
Number of Products by Stage and Top 10 Target, H1 2014 89
Number of Products by Top 10 Mechanism of Action, H1 2014 92
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 93
Number of Products by Top 10 Route of Administration, H1 2014 96
Number of Products by Stage and Top 10 Route of Administration, H1 2014 97
Number of Products by Top 10 Molecule Type, H1 2014 98
Number of Products by Stage and Top 10 Molecule Type, H1 2014 99
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hypertension Overview 10
Therapeutics Development 11
Pipeline Products for Hypertension - Overview 11
Pipeline Products for Hypertension - Comparative Analysis 12
Hypertension - Therapeutics under Development by Companies 13
Hypertension - Therapeutics under Investigation by Universities/Institutes 18
Hypertension - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Hypertension - Products under Development by Companies 24
Hypertension - Products under Investigation by Universities/Institutes 29
Hypertension - Companies Involved in Therapeutics Development 30
Sanofi 30
Eli Lilly and Company 31
GlaxoSmithKline plc 32
Daiichi Sankyo Company, Limited 33
Merck & Co., Inc. 34
Takeda Pharmaceutical Company Limited 35
BioLineRx, Ltd. 36
Novartis AG 37
Biocon Limited 38
Chong Kun Dang Pharmaceutical Corp. 39
Daewoong Pharmaceutical Co., Ltd. 40
Mitsubishi Tanabe Pharma Corporation 41
Bayer AG 42
Toray Industries, Inc. 43
IntelGenx Corp. 44
Medivir AB 45
Compugen Ltd. 46
Palatin Technologies, Inc. 47
Cytokinetics, Incorporated 48
Yuhan Corporation 49
Torrent Pharmaceuticals Limited 50
HanAll Biopharma Co., Ltd. 51
Ahn-Gook Pharmaceutical Co., Ltd. 52
LG Life Sciences, Ltd. 53
DiaMedica Inc. 54
AFFiRiS AG 55
CJ CheilJedang Corp. 56
Ache Laboratorios Farmaceuticos S/A 57
Cyano Biotech GmbH 58
Anacor Pharmaceuticals, Inc. 59
AngioDesign 60
Innopharmax Inc. 61
QUANTUM GENOMICS Corp. 62
vasopharm GmbH 63
Cellceutix Corporation 64
Diakron Pharmaceuticals, Inc. 65
Biolink Group AS 66
miRagen Therapeutics, Inc. 67
MicroDose Therapeutx, Inc. 68
Vicore Pharma AB 69
Kotobuki Pharmaceutical Co., Ltd. 70
RedHill Biopharma Ltd. 71
Kadmon Pharmaceuticals, LLC 72
Ajinomoto Pharmaceuticals Co., Ltd. 73
Hanmi Pharmaceuticals, Co. Ltd. 74
NanoForm Therapeutics Ltd. 75
Arromax Pharmatech, Co. Ltd. 76
AbbVie Inc. 77
China Grand Wuhan General Pharmaceutical Research Institute 78
Hypertension - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 85
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 94
azilsartan medoxomil - Drug Profile 94
(azilsartan medoxomil + chlorthalidone) - Drug Profile 96
(cilnidipine + valsartan) - Drug Profile 97
(azilsartan + amlodipine besylate) - Drug Profile 98
(AHU-377 + valsartan) - Drug Profile 99
(atorvastatin calcium + losartan potassium) - Drug Profile 101
carvedilol CR - Drug Profile 102
(rosuvastatin + telmisartan) - Drug Profile 104
(irbesartan + atorvastatin calcium) - Drug Profile 105
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 106
ZV Combi - Drug Profile 107
pratosartan - Drug Profile 108
carvedilol CR - Drug Profile 109
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 110
(rosuvastatin + valsartan) - Drug Profile 111
CKD-825 - Drug Profile 112
(losartan potassium + hydrochlorothiazide + amlodipine besylate) - Drug Profile 113
XY-1014-KD-2 - Drug Profile 114
PL-3994 - Drug Profile 115
(atorvastatin calcium + losartan potassium) - Drug Profile 117
KD-027 - Drug Profile 118
CS-3150 - Drug Profile 120
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 121
LFF-269 - Drug Profile 122
Potassium Magnesium Citrate - Drug Profile 123
pratosartan - Drug Profile 124
dextromethorphan - Drug Profile 125
QGC-001 - Drug Profile 126
HPT-C/D-3G - Drug Profile 127
(amlodipine besylate + losartan potassium) - Drug Profile 128
(simvastatin + losartan potassium) - Drug Profile 129
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 130
(candesartan + amlodipine besylate) - Drug Profile 131
TAK-272 - Drug Profile 132
MK-7145 IR - Drug Profile 133
MP-157 - Drug Profile 134
AGSAV-301 - Drug Profile 135
MK-8150 - Drug Profile 136
(amlodipine + losartan) - Drug Profile 137
AGSAA-010 - Drug Profile 138
CARD-024 - Drug Profile 139
(rosuvastatin + amlodipine) - Drug Profile 141
(chlorthalidone + telmisartan) - Drug Profile 142
(amlodipine + enalapril maleate) - Drug Profile 143
RB-150 - Drug Profile 145
CJ-30058 - Drug Profile 147
Drug for Hypertension - Drug Profile 148
CGEN-856 - Drug Profile 149
CGEN-857 - Drug Profile 151
DP-3005 - Drug Profile 152
MetPril - Drug Profile 153
KM-732 - Drug Profile 154
Small Molecule to Inhibit Renin for Hypertension - Drug Profile 155
CK-2018571 - Drug Profile 156
doxazosin mesylate - Drug Profile 157
felodipine - Drug Profile 158
Vaccine For Hypertension - Drug Profile 159
epoetin alfa - Drug Profile 160
DM-204 - Drug Profile 161
olmesartan - Drug Profile 162
MGN-2677 - Drug Profile 163
C-21 - Drug Profile 164
GYY-4137 - Drug Profile 166
CK-2018488 - Drug Profile 167
BR-4628 - Drug Profile 168
GTP-0125 - Drug Profile 169
AGNBS-002 - Drug Profile 170
tannic acid - Drug Profile 171
Dual Action Receptor Antagonists - Drug Profile 172
AVE-3085 - Drug Profile 173
carvedilol CR - Drug Profile 174
Bone Morphogenic Protein Inhibitors - Drug Profile 175
Alanine Glyoxylate Aminotransferase-2 - Drug Profile 176
Drug Targeting AMPD2 - Drug Profile 177
AN-3485 - Drug Profile 178
AMX-1008 - Drug Profile 179
VAS-3947 - Drug Profile 180
Drug To Inhibit 11Beta-HSD1 For Hypertension - Drug Profile 181
Helix B Surface Peptide - Drug Profile 182
SOL-1 - Drug Profile 183
Small Molecule to Inhibit Epoxide Hydrolase for Hypertension - Drug Profile 184
TRC-120038 - Drug Profile 185
Peptide Compounds - Drug Profile 186
3,5-Disubstituted Piperidines - Drug Profile 187
Elsartan - Drug Profile 188
S-43126 - Drug Profile 189
TM-5441 - Drug Profile 190
siRNA to Inhibit Angiotensinogen for Hypertension - Drug Profile 191
Endothelin A Receptor Antagonists for Hypertension - Drug Profile 192
Small Molecule to Inhibit Mineralocorticoid Receptor for Hypertension - Drug Profile 193
AGNES-101 - Drug Profile 194
Angiotensin Converting Enzyme Inhibitors for Cardiovascular Diseases - Drug Profile 195
Tar-1 - Drug Profile 196
AZ-03 - Drug Profile 197
Microginins ACE Inhibitors- Program - Drug Profile 198
ROMK Channel Inhibitors - Drug Profile 199
R-100 - Drug Profile 200
(amlodipine camsylate + losartan potassium) - Drug Profile 202
metoprolol succinate - Drug Profile 203
Hypertension - Recent Pipeline Updates 204
Hypertension - Dormant Projects 214
Hypertension - Discontinued Products 223
Hypertension - Product Development Milestones 224
Featured News & Press Releases 224
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 231
Disclaimer 231
List of Tables
Number of Products under Development for Hypertension, H1 2014 18
Number of Products under Development for Hypertension - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Development, H1 2014 29
Comparative Analysis by Unknown Stage Development, H1 2014 30
Products under Development by Companies, H1 2014 31
Products under Development by Companies, H1 2014 (Contd..1) 32
Products under Development by Companies, H1 2014 (Contd..2) 33
Products under Development by Companies, H1 2014 (Contd..3) 34
Products under Development by Companies, H1 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Hypertension - Pipeline by Sanofi, H1 2014 37
Hypertension - Pipeline by Eli Lilly and Company, H1 2014 38
Hypertension - Pipeline by GlaxoSmithKline plc, H1 2014 39
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 40
Hypertension - Pipeline by Merck & Co., Inc., H1 2014 41
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 42
Hypertension - Pipeline by BioLineRx, Ltd., H1 2014 43
Hypertension - Pipeline by Novartis AG, H1 2014 44
Hypertension - Pipeline by Biocon Limited, H1 2014 45
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 46
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 47
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 48
Hypertension - Pipeline by Bayer AG, H1 2014 49
Hypertension - Pipeline by Toray Industries, Inc., H1 2014 50
Hypertension - Pipeline by IntelGenx Corp., H1 2014 51
Hypertension - Pipeline by Medivir AB, H1 2014 52
Hypertension - Pipeline by Compugen Ltd., H1 2014 53
Hypertension - Pipeline by Palatin Technologies, Inc., H1 2014 54
Hypertension - Pipeline by Cytokinetics, Incorporated, H1 2014 55
Hypertension - Pipeline by Yuhan Corporation, H1 2014 56
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 57
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 58
Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 59
Hypertension - Pipeline by LG Life Sciences, Ltd., H1 2014 60
Hypertension - Pipeline by DiaMedica Inc., H1 2014 61
Hypertension - Pipeline by AFFiRiS AG, H1 2014 62
Hypertension - Pipeline by CJ CheilJedang Corp., H1 2014 63
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 64
Hypertension - Pipeline by Cyano Biotech GmbH, H1 2014 65
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 66
Hypertension - Pipeline by AngioDesign, H1 2014 67
Hypertension - Pipeline by Innopharmax Inc., H1 2014 68
Hypertension - Pipeline by QUANTUM GENOMICS Corp., H1 2014 69
Hypertension - Pipeline by vasopharm GmbH, H1 2014 70
Hypertension - Pipeline by Cellceutix Corporation, H1 2014 71
Hypertension - Pipeline by Diakron Pharmaceuticals, Inc., H1 2014 72
Hypertension - Pipeline by Biolink Group AS, H1 2014 73
Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2014 74
Hypertension - Pipeline by MicroDose Therapeutx, Inc., H1 2014 75
Hypertension - Pipeline by Vicore Pharma AB, H1 2014 76
Hypertension - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2014 77
Hypertension - Pipeline by RedHill Biopharma Ltd., H1 2014 78
Hypertension - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 79
Hypertension - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 80
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 81
Hypertension - Pipeline by NanoForm Therapeutics Ltd., H1 2014 82
Hypertension - Pipeline by Arromax Pharmatech, Co. Ltd., H1 2014 83
Hypertension - Pipeline by AbbVie Inc., H1 2014 84
Hypertension - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute., H1 2014 85
Assessment by Monotherapy Products, H1 2014 86
Assessment by Combination Products, H1 2014 87
Number of Products by Stage and Target, H1 2014 90
Number of Products by Stage and Mechanism of Action, H1 2014 94
Number of Products by Stage and Route of Administration, H1 2014 97
Number of Products by Stage and Molecule Type, H1 2014 100
Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 211
Hypertension - Dormant Projects, H1 2014 221
Hypertension - Dormant Projects (Contd..1), H1 2014 222
Hypertension - Dormant Projects (Contd..2), H1 2014 223
Hypertension - Dormant Projects (Contd..3), H1 2014 224
Hypertension - Dormant Projects (Contd..4), H1 2014 225
Hypertension - Dormant Projects (Contd..5), H1 2014 226
Hypertension - Dormant Projects (Contd..6), H1 2014 227
Hypertension - Dormant Projects (Contd..7), H1 2014 228
Hypertension - Dormant Projects (Contd..8), H1 2014 229
Hypertension - Discontinued Products, H1 2014 230
List of Figures
Number of Products under Development for Hypertension, H1 2014 18
Number of Products under Development for Hypertension - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Products, H1 2014 29
Assessment by Monotherapy Products, H1 2014 86
Assessment by Combination Products, H1 2014 87
Number of Products by Top 10 Target, H1 2014 88
Number of Products by Stage and Top 10 Target, H1 2014 89
Number of Products by Top 10 Mechanism of Action, H1 2014 92
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 93
Number of Products by Top 10 Route of Administration, H1 2014 96
Number of Products by Stage and Top 10 Route of Administration, H1 2014 97
Number of Products by Top 10 Molecule Type, H1 2014 98
Number of Products by Stage and Top 10 Molecule Type, H1 2014 99
